Patients on maintenance hemodialysis have dysregulations of calcium and phosphorus homeostasis which results in a plethora of mineral and bone pathologies. Management is typically focused on maintenance eucalcemia and limiting hyperphosphatemia while avoiding extremes of intact parathyroid hormone. Hypercalcemia in this setting is often iatrogenic. We present a case of humoral hypercalcemia of malignancy initially thought to be iatrogenic due to mineral bone management and discuss the overlap of management of hypercalcemia and management of mineral bone disease in end stage kidney disease. We highlight the relationship between malignancy and end stage kidney disease and the increased risk of hypercalcemia associated with malignancy.
GoldsteinDA.Serum Calcium. In: WalkerHKHallWDHurstJW (eds) Clinical methods: the history, physical, and laboratory examinations. Boston: Butterworths, 1990.
2.
HruskaKASeifertMSugataniT.Pathophysiology of the chronic kidney disease-mineral bone disorder. Curr Opin Nephrol Hypertens2015; 24: 303–309.
3.
KettelerMBlockGAEvenepoelP, et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int2017; 92: 26–36.
4.
ButlerAMOlshanAFKshirsagarAV, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis2015; 65: 763–772.
5.
GastanagaVMSchwartzbergLSJainRK, et al. Prevalence of hypercalcemia among cancer patients in the United States. Cancer Med2016; 5: 2091–2100.
6.
Chavez-AbiegaSMosICentenoPP, et al. Sensing extracellular calcium - an insight into the structure and function of the Calcium-Sensing Receptor (CaSR). Adv Exp Med Biol2020; 1131: 1031–1063.
7.
KhundmiriSJMurrayRDLedererE.PTH and Vitamin D. Compr Physiol2016; 6: 561–601.
8.
CrowleyRGittoesN.How to approach hypercalcaemia. Clin Med (Lond)2013; 13: 287–290.
9.
WaziriBDuarteRNaickerS.Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): current perspectives. Int J Nephrol Renovasc Dis2019; 12: 263–276.
10.
de Brito GalvaoJFNagodeLASchenckPA, et al. Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease. J Vet Emerg Crit Care (San Antonio)2013; 23: 134–162.
11.
RivaraMBRavelVKalantar-ZadehK, et al. Uncorrected and albumin-corrected calcium, phosphorus, and mortality in patients undergoing maintenance dialysis. J Am Soc Nephrol2015; 26: 1671–1681.
12.
2019 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2019.
13.
TentoriFBlayneyMJAlbertJM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis2008; 52: 519–530.
14.
YoshikawaMTakaseOTsujimuraT, et al. Long-term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: a systematic review and meta-analysis. Sci Rep2018; 8: 5310.
15.
SpasovskiGGelevSMasin-SpasovskaJ, et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone2007; 41: 698–703.
16.
JadoulMAlbertJMAkibaT, et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int2006; 70: 1358–1366.
17.
StewartAF.Clinical practice. Hypercalcemia associated with cancer. N Engl J Med2005; 352: 373–379.
18.
NordholmARixMOlgaardK, et al. Parathyroid hormone-related peptide plasma concentrations in patients on hemodialysis. Scand J Clin Lab Invest2014; 74: 206–212.
19.
OrloffJJSoiferNEFoderoJP, et al. Accumulation of carboxy-terminal fragments of parathyroid hormone-related protein in renal failure. Kidney Int1993; 43: 1371-1376.
